NCT02982694 is a Phase 2 clinical trial of Atezolizumab in MSI, sponsored by Vall d'Hebron Institute of Oncology.

Who is sponsoring NCT02982694?

NCT02982694 is sponsored by Vall d'Hebron Institute of Oncology.

What drugs are being tested in NCT02982694?

Interventions in NCT02982694: Atezolizumab, Bevacizumab.

What condition does NCT02982694 study?

NCT02982694 studies MSI, ColoRectal Cancer, Chemotherapy, Resistance, APC.

Is NCT02982694 still recruiting?

NCT02982694 is currently terminated. Last updated 1 October 2025.

Last reviewed 2025-10-01 · How we verify

NCT02982694

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

Terminated Phase 2 Last updated 1 October 2025

What this trial tests

Phase 2 trial testing Atezolizumab in MSI in 46 participants. Terminated before completion.

Timeline

24 November 2017

Primary endpoint
27 November 2020

27 November 2020

Quick facts

Lead sponsor	Vall d'Hebron Institute of Oncology
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	24 November 2017
Primary completion	27 November 2020
Estimated completion	27 November 2020
Sites	7 locations across Belgium, Italy, Netherlands, Spain

Drugs / interventions tested

Atezolizumab (atezolizumab) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →

Conditions studied

MSI — all drugs for MSI →
ColoRectal Cancer — all drugs for ColoRectal Cancer →
Chemotherapy — all drugs for Chemotherapy →
Resistance, APC — all drugs for Resistance, APC →

Sponsor

Vall d'Hebron Institute of Oncology

Who can join

18 and older, any sex, with MSI or ColoRectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to determine the anti-tumor activity, as measured by overall response rate (ORR) of atezolizumab in combination with bevacizumab in patients with chemotherapy resistant CRC and positivity for MSI-like molecular signature. This is an international, open-label single arm (non-randomized), one-stage phase II trial.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.
Battaglin F, Naseem M, Lenz HJ, Salem ME. · · 2018 · cited 163× · PMID 30543589
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy.
Ai L, Chen J, Yan H, He Q, et al · · 2020 · cited 149× · PMID 32982171 · DOI 10.2147/dddt.s267433
PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies.
Lin KX, Istl AC, Quan D, Skaro A, et al · · 2023 · cited 90× · PMID 37831146 · DOI 10.1007/s00262-023-03520-5
Tumor Vasculatures: A New Target for Cancer Immunotherapy.
Liu Z, Wang Y, Huang Y, Kim BYS, et al · · 2019 · cited 88× · PMID 31331639 · DOI 10.1016/j.tips.2019.07.001
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
Li SJ, Chen JX, Sun ZJ. · · 2021 · cited 63× · PMID 34137513 · DOI 10.1002/cac2.12183
Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.
Comunanza V, Bussolino F. · · 2017 · cited 62× · PMID 29270405 · DOI 10.3389/fcell.2017.00101
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.
Taieb J, Jung A, Sartore-Bianchi A, Peeters M, et al · · 2019 · cited 49× · PMID 31347092 · DOI 10.1007/s40265-019-01165-2
Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy.
Chatterjee S, Lesniak WG, Nimmagadda S. · · 2017 · cited 46× · PMID 28707500 · DOI 10.1177/1536012117718459

Verify or expand the search:

Other trials of Atezolizumab

Trials testing the same drug.

NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec · Phase 3 · not yet recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other recruiting trials for MSI

Currently open trials in the same condition.

NCT05495776 — Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer · recruiting

Other Vall d'Hebron Institute of Oncology trials

Trials by the same sponsor.

NCT06411600 — Combination Therapy for BRAF-V600E Metastatic CRCm · Phase 2 · recruiting
NCT05385705 — A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refracto · Phase 1 · terminated
NCT06680739 — Single cEll pRofiling PErsistaNce To ImmuNothErapy · Phase 2 · recruiting
NCT05141474 — Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte ( · EARLY_PHASE1 · recruiting
NCT05534178 — Machine Learning Model to Predict HOLS and Mortality After Discharge in Hospitalized Oncologic Patients · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02982694 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vall d'Hebron Institute of Oncology
Last refreshed: 1 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02982694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing